<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00325546</url>
  </required_header>
  <id_info>
    <org_study_id>EFC6001</org_study_id>
    <nct_id>NCT00325546</nct_id>
  </id_info>
  <brief_title>Study of Weight-Reducing Effect and Safety of Rimonabant In Obesity in ASIA (RIO-ASIA)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose (Rimonabant 20mg), Multi-National, Multicentre Study of Weight-Reducing Effect and Safety of Rimonabant in Obese Patients With or Without Comorbidities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary : effect on weight loss and weight maintenance over 9 months when prescribed with a
      hypocaloric diet in obese patients.

      Secondary : effect on HDL-Cholesterol, triglycerides, fasting-insulin, fasting glucose, waist
      circumference - safety and tolerability
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in weight from baseline to month 9</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>HDL-Cholesterol, triglycerides, fasting-insulin, fasting glucose, waist circumference(physical examination, vital signs, ECG, laboratory tests, adverse events).</measure>
  </secondary_outcome>
  <enrollment type="Actual">643</enrollment>
  <condition>Obesity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rimonabant (SR141716)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI)&gt; 25 kg/mÂ²

        Exclusion Criteria:

          -  Absence of stable weight (variation &lt; 5 kg) within three months prior to screening
             visit),

          -  Absence of effective contraceptive method for females of childbearing potential,

          -  Presence of treated or untreated type 1 or type 2 diabetes,

          -  Systolic blood pressure &gt; 165 mm Hg and/or diastolic blood pressure &gt; 105 mm Hg on 2
             consecutive visits from the screening to the inclusion visit,

          -  Presence of secondary hypertension,

          -  Patients with conditions/concomitant diseases making them non evaluable for the
             primary efficacy endpoint (presence of any clinically significant endocrine disease
             according to the Investigator, obesity of known endocrine origin...)

          -  Presence of any severe medical or psychological condition or chronic
             conditions/infections that in the opinion of the Investigator would compromise the
             patient's safety or successful participation in the study,

          -  Presence of any clinically significant abnormality according to the Investigator on
             the ECG performed on the inclusion visit.

          -  Presence or history of cancer within the past five years with the exception of
             adequately treated localized basal cell skin cancer or in situ uterine cervical
             cancer.

          -  Related to previous or concomitant medications :

               -  Drugs affecting weight (e.g., sibutramine, orlistat, herbal preparations, etc).

               -  Antidiabetic drugs.

          -  Related to laboratory findings:

               -  Positive test for hepatitis B surface antigen and/or hepatitis C antibody.

               -  Abnormal TSH level (TSH &gt; ULN or &lt; LLN).

               -  Positive urine pregnancy test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Shangai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Seoul</city>
        <zip>135-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Taipei</city>
        <zip>105</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2006</study_first_submitted>
  <study_first_submitted_qc>May 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2006</study_first_posted>
  <last_update_submitted>April 6, 2009</last_update_submitted>
  <last_update_submitted_qc>April 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rimonabant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

